ICER releases evidence report on acute treatments for migraine

10 January 2020 - Lasmiditan, rimegepant, and ubrogepant all perform better than placebo, but evidence is not adequate to distinguish among ...

Read more →

Human medicines: highlights of 2019

9 January 2020 - EMA has published a review of its key recommendations in 2019 on the authorisation and safety ...

Read more →

ICER issues final report and policy recommendations on JAK inhibitors for rheumatoid arthritis

9 January 2020 - Despite upadacitinib reaching common thresholds for cost-effectiveness when compared to adalimumab, the independent appraisal committee’s votes on ...

Read more →

PBAC Public Summary Documents - August 2019 intracycle meeting

13 December 2019 - The Public Summary Document for a review into antibiotics on the PBS from the August 2019 ...

Read more →

PBS expenditure and prescriptions report 2018-19

13 December 2019 - The PBS Expenditure and Prescriptions Report 1 July 2018 to 30 June 2019 is now available. ...

Read more →

ICER releases evidence report on JAK inhibitors to treat rheumatoid arthritis

26 November 2019 - Using adalimumab as the comparator, upadacitinib’s value-based price benchmark is between $44,000-$45,000 per year; at December 9 ...

Read more →

PBAC Public Summary Documents - July 2019 meeting

15 November 2019 - The Public Summary Documents (first time rejections and deferrals) from the July 2019 PBAC meeting are now ...

Read more →

Drug Utilisation Sub-Committee outcome statement

13 November 2019 - The outcome statement from the October 2019 Drug Utilisation Sub-Committee meeting is now available. ...

Read more →

PBAC Public Summary Documents - May 2019 meeting

1 November 2019 - The Public Summary Documents from the May 2019 PBAC intracycle meeting are now available. ...

Read more →

Annual performance statistics report: July 2018 to June 2019

21 October 2019 - At 30 June 2019 there were 88,788 therapeutic goods on the ARTG, including 31,987 new products added ...

Read more →

ICER releases updated draft evidence report on rheumatoid arthritis therapies

11 October 2019 - Public comment period extended through 8 November 2019; public meeting now to take place on 9 December ...

Read more →

High health care costs suggest review is needed: report

8 October 2019 - The federal government’s annual $6 billion spend on the health insurance rebate could be redirected to ...

Read more →

ICER releases draft evidence report on rheumatoid arthritis therapies

26 September 2019 - Public comment period now open until 24 October 2019; requests to make oral comment during public ...

Read more →

ICER publishes evidence report on additive cardiovascular disease therapies

12 September 2019 - Pricing of rivaroxaban and icosapent ethyl aligns well with treatments’ benefits for patients; expert roundtable will discuss ...

Read more →

ICER releases draft evidence report on diabetes therapies

11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting ...

Read more →